The team reports that MYOF emerges as a novel therapeutic target in glioblastoma, linking the gene’s activity to key processes that help tumors survive and expand. Instead of treating glioblastoma as a single-pathway problem, the study frames MYOF as part of a mechanistic network—one that can be exploited when disrupted.

Using a combination of molecular profiling and functional experiments, the researchers mapped how MYOF influences tumor-relevant signaling. They observed that altering MYOF activity changes cellular behavior consistent with impaired malignancy, suggesting MYOF is not merely associated with disease state but actively contributes to tumor fitness.

Importantly, the work extends beyond biology into the realm of therapy development. The authors describe drug discovery efforts guided by the mechanistic insights from MYOF’s role, emphasizing how target definition can accelerate the search for compounds with meaningful effects in glioblastoma models.

While the study focuses on MYOF, it also highlights a broader theme: effective glioblastoma therapies may require intercepting specific nodes that coordinate multiple cancer traits. By targeting MYOF, the researchers aim to undermine the tumor’s ability to maintain its malignant programs.

The findings also propose how MYOF modulation could influence pathways tied to survival under stress, a hallmark of aggressive tumor behavior. In this sense, the target is positioned as a potential lever to weaken glioblastoma resilience rather than simply slowing growth.

The researchers conclude that MYOF warrants further investigation as a candidate for preclinical development, with additional work needed to validate performance across diverse tumor contexts. If subsequent studies confirm the results, MYOF could become a practical target for next-generation glioblastoma therapeutics.

The paper appears in Cell Death Discoveries (2026) under DOI: https://doi.org/10.1038/s41420-026-03254-0.

Subject of Research: glioblastoma; MYOF as a therapeutic target
Article Title: Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery.
Article References: Zhao, P., Chen, Z., Zhu, J. et al. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03254-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03254-0

Glioblastoma represents the most common and lethal form of primary brain cancer, characterized by rapid growth and an intricate ability to evade immune system attacks. A critical barrier to effective treatment has been the tumor’s complex interaction with the immune microenvironment, particularly its manipulation of macrophages—immune cells fundamentally tasked with defending the body against pathogens. Glioblastoma cunningly reprograms these macrophages within its milieu, transforming them into accomplices that support tumor survival, promote growth, and suppress anti-tumor immune responses, thereby creating a protective niche against therapeutic intervention.

Central to this innovative therapeutic design is the identification of Glycoprotein non-metastatic melanoma protein B (GPNMB), a protein abundantly expressed both on glioblastoma cancer cells and the tumor-supportive macrophages. The dual presence of GPNMB in both malignant and immune-supportive cells presented researchers with a unique target: engineering a treatment capable of neutralizing the tumor itself while simultaneously dismantling its immunological sanctuary. This multifaceted approach represents a paradigm shift from traditional therapies that focus solely on eradicating cancer cells without addressing the enabling immune microenvironment.

Leveraging the revolutionary modality of Chimeric Antigen Receptor T-cell therapy (CAR-T), the McMaster team engineered immune effector cells to recognize and bind to GPNMB. CAR-T therapy, which has demonstrated remarkable efficacy in certain hematologic malignancies, involves genetically modifying patient-derived T cells to express receptors that specifically target tumor-associated antigens. In this application, CAR-T cells were tailored to identify GPNMB-expressing cells, enabling a concurrent assault on the cancerous tumor cells and the supportive macrophage population that fosters tumor growth and immune evasion.

Dr. Sheila Singh, senior author and professor of surgery at McMaster, emphasizes the conceptual evolution underlying this research. “Treating glioblastoma requires viewing it not merely as a conglomerate of malignant cells but as a complex ecosystem,” she explains. “Our strategy disrupts this ecosystem by simultaneously taking down both the tumor components and the immune cells that protect and nurture it. This dual-action approach moves us toward eradicating both tumor and its immunosuppressive shield.”

Preclinical investigations encompassing multiple models of glioblastoma, including those directly derived from human patient tumors, have yielded compelling results. These models demonstrated complete elimination of detectable tumors following CAR-T therapy targeting GPNMB and subsequent sustained remission, highlighting the durability of the antitumor response elicited by this approach. Such promising preclinical outcomes strongly suggest the potential for clinical translation, with the goal of overcoming glioblastoma’s notorious treatment resistance and improving patient survival.

This research builds upon prior efforts that explored GPNMB as an immunotherapeutic target across various cancer types. Notably, an initial human clinical trial at the University of Calgary employed GPNMB-specific CAR-T therapy to treat metastatic sarcoma—a cancer originating in connective tissues—with encouraging findings recently published in Nature Cancer. Such cross-cancer applicability underscores GPNMB’s promise as a broadly relevant target and affirms the translational potential of therapies aimed at this molecule.

Despite significant progress, several challenges remain before this innovative therapy can be introduced into clinical practice for glioblastoma patients. The central nervous system’s unique environment, potential off-target effects, and the need for long-term safety evaluation necessitate further rigorous investigation. Dr. Shan Grewal, co-lead author and MD/PhD candidate at McMaster, underscores the intricacy: “While CAR-T therapies have revolutionized treatment for certain blood cancers, their application to brain tumors has faced hurdles. Our findings indicate that targeting both the tumor and the immune system components that sustain it might be the key to unlocking efficacy in such complex solid tumors.”

This study exemplifies a concerted collaborative effort, uniting researchers from prestigious institutions including King’s College London, Northwestern University, the University of Calgary, the University of Toronto, and The Hospital for Sick Children. This multidisciplinary partnership fuses expertise in oncology, immunology, neurosurgery, and molecular biology, fostering comprehensive investigation into this ambitious therapeutic concept.

The researchers acknowledge funding support from numerous prominent organizations devoted to cancer and brain research, including the Terry Fox Research Institute, Brain Canada, the Cancer Research Society, Brain Cancer Canada, and the Brain Tumour Foundation of Canada. Such financial backing underscored the importance and societal urgency of advancing treatment options for devastating brain cancers.

This innovative CAR-T approach, which simultaneously disrupts glioblastoma tumors and their immunosuppressive microenvironment, signifies a hopeful stride forward in neuro-oncology. By addressing the tumor-immune ecosystem as an integrated therapeutic target, this research charts a promising course toward more effective and durable treatments for glioblastoma, setting the stage for forthcoming clinical trials and ultimately, improved patient outcomes in a cancer type that has long defied cure.

Subject of Research: Glioblastoma immunotherapy targeting tumor and tumor-associated macrophages via GPNMB-specific CAR-T cells.

Article Title: (Not provided in the source content)

News Publication Date: 1-Jul-2026

Keywords: glioblastoma, cancer immunotherapy, CAR-T therapy, GPNMB, tumor-associated macrophages, brain cancer, tumor microenvironment, glioma, immuno-oncology, McMaster University, tumor-immune ecosystem

Glioblastoma multiforme (GBM) remains one of the most formidable cancers to treat, due to its aggressive nature and resistance to conventional therapies. The standard of care involving surgery, radiation, and chemotherapy often fails to prevent relapse, highlighting the urgent need for innovative treatment options. The research by Mori et al. focused on the metabolic dependencies of GBM cells, particularly their reliance on cysteine—a pivotal amino acid for maintaining antioxidant defense through glutathione (GSH) synthesis.

At the core of this study is xCT, a membrane cystine/glutamate antiporter encoded by the SLC7A11 gene. xCT imports cystine, the oxidized form of cysteine, into cells, where it is reduced to cysteine, fueling glutathione biosynthesis. Glutathione, a major cellular antioxidant, scavenges reactive oxygen species (ROS) and maintains redox homeostasis. Cancer cells often upregulate xCT to counteract oxidative stress, supporting their survival and proliferation in hostile tumor microenvironments.

Interestingly, Mori’s team identified GGCT—a gamma-glutamyl cyclotransferase enzyme involved in the gamma-glutamyl cycle—as a complementary regulator of cysteine metabolism. GGCT participates in the degradation of gamma-glutamyl peptides, indirectly influencing intracellular cysteine availability and glutathione turnover. The dual targeting of xCT and GGCT effectively disrupts the cysteine supply chain, leading to a critical depletion of this amino acid within glioblastoma cells.

Mechanistically, cysteine depletion impairs glutathione synthesis, precipitating an accumulation of lipid peroxides and oxidative damage. This oxidative stress overload instigates ferroptosis, characterized by iron-dependent lipid peroxidation and membrane damage. Unlike apoptosis or necrosis, ferroptosis represents a distinct form of cell death with unique biochemical signatures. By harnessing ferroptosis, therapeutic strategies can eliminate cancer cells that have developed resistance to traditional apoptotic pathways.

The researchers employed a series of sophisticated in vitro experiments to validate their findings. Upon treatment with inhibitors specific for xCT and GGCT, glioblastoma cell lines exhibited markedly reduced viability, increased markers of oxidative stress, and characteristic hallmarks of ferroptosis. Notably, these effects were significantly attenuated when cells were supplemented with exogenous cysteine or treated with lipophilic antioxidants, underscoring the central role of cysteine availability and redox balance in ferroptosis induction.

Beyond cellular assays, the study explored potential biochemical feedback mechanisms that glioblastoma cells might deploy to circumvent cysteine depletion. The dual inhibition strategy appears to circumvent compensatory metabolic rewiring, suggesting that concomitant targeting of multiple enzymes within cysteine metabolism effectively locks cancer cells into a lethal oxidative dilemma.

The therapeutic implications of this research are profound. Current ferroptosis-based therapies are in nascent stages, often hampered by the challenge of selectively inducing ferroptosis in cancerous cells without detrimental effects on normal tissues. By delineating the synergistic effect of xCT and GGCT inhibition, Mori et al. provide a rationale for developing combination drugs or multi-target inhibitors that exploit cancer-specific metabolic vulnerabilities.

Moreover, this dual inhibition approach may synergize with existing treatment modalities. For example, radiation therapy, known to generate ROS, could be combined with metabolic blockade to overwhelm tumor antioxidant defenses. Such strategies hold promise for transforming glioblastoma from a terminal diagnosis into a manageable disease.

Future research directions highlighted by the authors include exploring the tumor microenvironment’s role in modulating ferroptosis sensitivity. Since glutamate exchange via xCT also influences extracellular neurotransmitter levels, the neurobiological repercussions of this therapeutic strategy require careful investigation to avoid unintended neurotoxicity.

Additionally, the development of selective, brain-penetrant inhibitors for xCT and GGCT is critical for clinical translation. The blood-brain barrier represents a formidable obstacle in drug delivery for central nervous system tumors, necessitating innovative pharmaceutical engineering to ensure adequate bioavailability.

The study also raises intriguing questions about the metabolic plasticity of glioblastoma cells. Understanding whether different glioblastoma subtypes exhibit variable dependence on xCT and GGCT could facilitate patient stratification and personalized therapy design. Biomarkers predictive of ferroptosis susceptibility would be invaluable for optimizing treatment regimens and monitoring therapeutic efficacy.

In summary, the dual targeting of xCT and GGCT to induce ferroptosis represents a paradigm shift in glioblastoma therapy, focusing on metabolic sabotage and redox dysregulation. By depleting cysteine and disabling antioxidant defenses, this approach circumvents resistance mechanisms and triggers a lethal cascade of oxidative damage within tumor cells.

As the war against glioblastoma intensifies, insights from this study illuminate a powerful new weapon in the oncologist’s arsenal. The convergence of metabolism, oxidative stress, and programmed cell death pathways heralds an era of precision medicine that can strategically dismantle cancer’s defenses from within.

Researchers and clinicians alike eagerly anticipate further preclinical and clinical studies to validate and refine this approach. Should these findings translate successfully into therapeutic gains, the prognosis for glioblastoma patients may witness a transformational improvement, shifting the landscape of neuro-oncology forever.

Subject of Research: Dual inhibition of xCT and GGCT to induce ferroptosis in glioblastoma cells.

Article Title: Dual inhibition of xCT and GGCT induces ferroptosis in glioblastoma cells by depleting cysteine and disrupting redox homeostasis.

Article References:
Mori, M., Ii, H., Matsumura, M. et al. Dual inhibition of xCT and GGCT induces ferroptosis in glioblastoma cells by depleting cysteine and disrupting redox homeostasis. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03108-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03108-9

Glioblastoma is notorious for its aggressive nature and poor patient survival, with standard-of-care treatments rarely extending life beyond 14 to 16 months post-diagnosis. The heterogeneity of this malignancy, compounded by molecular subtypes resistant to existing chemotherapy agents, underscores the urgent need for innovative treatment modalities. Recognizing this, the research team embarked on a mission to dissect the molecular underpinnings of glioblastoma’s resilience. They identified the myosin motor proteins—fundamental components that convert chemical energy into mechanical forces within cells—as key facilitators in tumor expansion and resistance mechanisms.

Myosin motors operate within a cellular environment much like miniature machines, orchestrating diverse processes such as motility, shape change, and intracellular transport. Their critical involvement in muscle cells is well-known, but their role in pathological states, including cancer progression, has remained largely unexploited due to the scarcity of selective pharmacological inhibitors. This gap presented both a challenge and an opportunity. By engineering a suite of small-molecule inhibitors capable of selectively incapacitating myosin motors involved in glioblastoma pathology, the team aimed to disrupt the cancer’s cellular machinery at a fundamental level.

The medicinal chemistry efforts, helmed by Dr. Theodore Kamenecka in collaboration with structural biologist Dr. Patrick Griffin, culminated in the synthesis of MT-125, a molecule specifically designed to inhibit non-muscle myosin II (NMII) functions within malignant cells. Early experimental models revealed that MT-125 impedes the contractile forces that cancer cells deploy to invade adjacent brain tissue, effectively "locking" them in place. This biophysical blockade stifles the tumor’s notorious ability to infiltrate and colonize new niches within the brain, which is a primary factor contributing to patient mortality.

A hallmark discovery in the research was MT-125’s ability to convert glioblastoma cells from radiation-resistant phenotypes into radiation-sensitive ones. Treated cells exhibited multinucleation—a condition where cells fail to undergo proper division and become marked for programmed cell death. This mechanistic insight was corroborated through murine models, where MT-125, both as a monotherapy and in combination with the kinase inhibitor sunitinib, elicited dramatic tumor regressions. These findings suggest a synergistic augmentation of existing chemotherapeutic regimens, opening avenues for combinatorial therapies with enhanced potency.

Despite the promising outcomes, the researchers caution against premature extrapolation to human clinical success. The biological divergence between murine models and human patients necessitates cautious optimism, with comprehensive toxicity profiling and dosing strategies integral to future studies. Notably, MT-125 displays preferential toxicity towards cancer cells over healthy tissue and possesses a pharmacokinetic profile suitable for pulsed administration, which may mitigate adverse effects commonly associated with chemotherapy.

The therapeutic significance of targeting molecular motors extends beyond glioblastoma. The science behind MT-125 opens a new frontier where disabling the mechanical underpinnings of malignant cells can be harnessed across a spectrum of cancers, potentially transforming treatment paradigms. Such a strategy veers away from traditional methods that primarily target genetic signals, focusing instead on the biophysical mechanisms essential to tumor progression.

In parallel with their oncology research, the team is advancing a related compound, MT-110, which holds promise in addressing methamphetamine use disorder by modulating myosin motor-driven neuronal pathways associated with drug craving. This illustrates the broad therapeutic potential of myosin motor inhibitors, resonating beyond cancer treatment to neurological and psychiatric diseases.

The pathway to bringing MT-125 from bench to bedside is well underway. The compound has been licensed to Myosin Therapeutics, a biotechnology startup founded by the principal investigators. With FDA approval granting clearance to initiate clinical trials, the team anticipates enrolling glioblastoma patients within the year. Substantial funding from the National Institutes of Health and dedicated glioblastoma research endowments supports this ambitious effort, laying the foundation for translational success.

Clinical trials will critically evaluate safety, dosing regimens, and efficacy in the complex and heterogeneous landscape of human glioblastoma. If successful, MT-125 could herald a new era where intractable brain tumors are rendered vulnerable to existing therapies, dramatically improving patient outcomes that have remained stagnant for decades.

This landmark research embodies the impact of interdisciplinary collaboration—melding medicinal chemistry, structural biology, neuro-oncology, and clinical expertise—to tackle one of the most formidable challenges in cancer treatment. By reimagining glioblastoma therapy through the lens of cellular mechanics, the scientists have illuminated a transformative therapeutic axis poised to advance the future of oncology.

Subject of Research: Animals

Article Title: Scientists wipe out aggressive brain cancer tumors by targeting cellular ‘motors’

News Publication Date: 1-Jul-2025

Web References:

• Research article in Cell: https://www.cell.com/cell/fulltext/S0092-8674(25)00569-0
• DOI link: http://dx.doi.org/10.1016/j.cell.2025.06.006

Image Credits: Image courtesy Steven Rosenfeld, M.D., Ph.D., and Courtney Miller, Ph.D.

Keywords: Glioblastomas, Brain cancer, Cancer